Drug Discovery

The pharmaceutical industry is currently witnessing a transformative shift in drug development as researchers move beyond the limitations of traditional small-molecule inhibitors toward the sophisticated field of Targeted Protein Degradation. While conventional therapies often focus on blocking the

Deep within the intricate labyrinth of the human brain, a silent and often invisible architect may be weaving a cluster of fragile, mulberry-shaped vessels that threaten to rupture at any given moment. These structural anomalies, known as Cerebral Cavernous Malformations (CCMs), are far more common

The persistent challenge of managing nonsegmental vitiligo often leaves patients with limited choices beyond topical applications that frequently fail to address the systemic nature of the autoimmune response. While many dermatological conditions have seen a revolution in biological therapies,

The pharmaceutical industry is currently witnessing a profound shift as researchers move away from traditional two-dimensional cell cultures toward complex three-dimensional architectures that more accurately reflect the intricate physiological environment of the human body. This transition is

The biochemical landscape of the human body has long been viewed as a battlefield where antioxidants act as the primary defense against the cellular wear and tear that leads to chronic disease. For generations, glutathione has occupied the throne as the "master antioxidant," an essential molecule

Ivan Kairatov is a leading biopharma expert with a profound background in molecular oncology and therapeutic innovation. His extensive research in drug development has centered on the complex interplay between tumor biology and the microenvironment, particularly how cellular communication drives